Targeted Radionuclide Therapy in Metastatic Prostate Cancer Using a New PSMA Ligand Radiolabelled With Terbium-161 (161Tb-SibuDAB) - Dose Identification/Escalation Phase Ia/b Study

Researchers will test a new treatment for prostate cancer. This treatment uses an antibody tagged with a small amount of radioactive material. Researchers believe the new antibody might work better than those used before. In the first part of the study researchers will compare the new treatment to the old one on prostate cancer patients using very low doses, not strong enough to treat nor to cause strong adverse reactions. Each patient will eventually receive both treatments, but one at a time. The aim of the second part of the study is to find the best dose of the new treatment for patients

Trial Details

NCT ID
NCT06343038
Phase
PHASE1
Sponsor
University Hospital, Basel, Switzerland
Status
RECRUITING
Cancer Type
Prostate Cancer
Interventions
  • Injection, 161Tb-SibuDAB,1GBq
  • Injection, 177Lu-PSMA-I&T, 1GBq
  • Injection, 161Tb-SibuDAB, Dose Escalation
Locations (sample)
  • Basel, Switzerland|47.55839,7.57327

Key Eligibility Criteria

  • Consent form signed
  • Male patients with age \> 18 years
  • Clinical indication for RLT with 177Lu-PSMA-I\&T (progressive PSMA-positive mCRPC patients after androgen receptor signalling pathway inhibitor and…
  • Patients will be included in Phase Ia while being under active therapy with 177Lu-PSMA-I\&T (SoC) and after they have completed the first two cycle…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →